Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulating co-stimulation.

Vissia Viglietta1, Samia J Khoury

  • 1Clinical Immunology Laboratory, Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. vviglietta@rics.bwh.harvard.edu

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|October 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis.

Annals of clinical and translational neurology·2026
Same author

Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis: Systematic Review and Meta-Analysis.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal of neurology·2026
Same author

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

CNS drugs·2026
Same author

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Therapeutic advances in neurological disorders·2026
Same author

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Neurology·2026
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Brain interstitial fluid pharmacokinetics and therapeutic effect of a BBB penetrating amyloid beta antibody measured by microdialysis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Blocking co-stimulatory pathways, like CD28-B7, offers a new way to treat autoimmune diseases. This approach prevents T-cell activation, reducing inflammation and disease progression in both animal models and human clinical trials.

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Therapeutic Strategies

Background:

  • Autoimmune diseases involve auto-reactive CD4+ T cells driving inflammation.
  • Co-stimulatory pathways are crucial for T-cell activation and immune responses.
  • Modulating these pathways presents a novel therapeutic avenue.

Purpose of the Study:

  • To review the role of co-stimulatory pathways, especially CD28-B7, in autoimmune diseases.
  • To present evidence from in vivo and in vitro studies on co-stimulation blockade efficacy.
  • To discuss the clinical application of blocking agents in human autoimmune diseases.

Main Methods:

  • Review of existing literature on co-stimulatory pathways and autoimmune diseases.
  • Analysis of in vivo and in vitro studies in animal models.

Related Experiment Videos

  • Evaluation of clinical trial data for blocking monoclonal antibodies.

    • Main Results:

    • Co-stimulatory pathways, particularly CD28-B7, are implicated in autoimmune disease pathogenesis.
    • Co-stimulation blockade demonstrates efficacy in preclinical animal models.
    • Clinical trials show potential for blocking agents in reducing T-cell activation in humans.

    Conclusions:

    • Inhibiting co-stimulatory molecule interactions via monoclonal antibodies is a promising strategy.
    • This approach offers a novel method for regulating autoimmune diseases.
    • Targeting co-stimulation provides a potential therapeutic intervention for human autoimmune conditions.